30 January 2024>: Clinical Research
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo
Edmond Komoni 1ABCDEFG , Fisnik Jashari 1ACD , Dren Boshnjaku 1DF , Blerim Myftiu 2BF , Melihate Pushka 1BF , Afrim Blyta 1A , Rajmonda Nallbani-Komoni 3ACEF*DOI: 10.12659/MSM.942992
Med Sci Monit 2024; 30:e942992
Figure 4 Comparison of the anti-SARS-CoV-2 antibodies between MS patients on different DMTs. (A) Error bars of anti-SARS-CoV-2 IgG titer in different DMTs. (B) Scatter plots of the anti-SARS-CoV-2 IgG titer between patients on interferons and Anti-CD20. MS – multiple sclerosis; DMT – disease-modifying therapy.